HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies.

Eileen Mary OReilly,Erkut Borazanci,Kenneth H. Yu,Anna M. Varghese,Hayley Estrella,David Kamins,Teresa J. Melink,Kirsten Dörr,Paul W. Maffuid,John Gutheil,Judy Sing-Zan Wang,Todd Michael Bauer

HuMab-5B1 (MVT-5873), a mAb targeting sLea, in combination with first-line gemcitabine plus nab-paclitaxel (gem/nab-P) for patients with pancreatic cancer (PDAC) and other CA19-9 positive malignancies.

2018

Eileen Mary OReilly
Erkut Borazanci
Kenneth H. Yu
Anna M. Varghese
Hayley Estrella
David Kamins
Teresa J. Melink
Kirsten Dörr
Paul W. Maffuid
John Gutheil
Judy Sing-Zan Wang
Todd Michael Bauer

e16235Background: MVT-5873, a fully human IgG1 mAb, targets sialyl Lewis A (sLea), an epitope on CA19-9. CA19-9 is expressed in PDAC and other GI and lung cancers, plays a role in tumor adhesion an...

Keywords:

Nab-paclitaxel
Pancreatic cancer
Pathology
CA19-9
Cancer research
Monoclonal antibody
Gemcitabine
Medicine
Epitope
first line
Sialyl-Lewis A

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations